NCT04416204

Brief Summary

The experimental approach in this study intends to investigate the role of hepatic glycogen content on nocturnal regulation of endogenous glucose production including the relative contributions of glycogenolysis and gluconeogenesis and the extent to which this differs between subjects with type 2 diabetes and subjects without diabetes. Both participants with type 2 diabetes and participants without diabetes will be studied after consuming either a low carbohydrate (no glycogen loading) or high carbohydrate (glycogen loading) diet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at below P25 for not_applicable diabetes-mellitus

Timeline
Completed

Started Aug 2020

Typical duration for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 4, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

August 21, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2023

Completed
10 months until next milestone

Results Posted

Study results publicly available

December 18, 2023

Completed
Last Updated

March 1, 2024

Status Verified

February 1, 2024

Enrollment Period

2 years

First QC Date

June 1, 2020

Results QC Date

September 27, 2023

Last Update Submit

February 28, 2024

Conditions

Keywords

Diabetes Mellitushepatic glycogenendogenous glucose production

Outcome Measures

Primary Outcomes (1)

  • Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes

    We measured the rates and contribution of Gluconeogenesis (GNG) to nocturnal Endogenous Glucose Production (EGP) using the deuterated water technique after either glycogen loading or no glycogen loading in subjects with type 2 diabetes.

    Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks

Secondary Outcomes (2)

  • Rates of Glycogenolysis in Subjects With Type 2 Diabetes

    Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks

  • Rates of Gluconeogenesis in Healthy Subjects

    Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks

Study Arms (2)

Type 2 diabetes

EXPERIMENTAL

Participants with Type 2 Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.

Other: glycogen loadingOther: No Glycogen Loading

Participants without diabetes

EXPERIMENTAL

Participants with no Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.

Other: glycogen loadingOther: No Glycogen Loading

Interventions

Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.

Participants without diabetesType 2 diabetes

Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.

Participants without diabetesType 2 diabetes

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 30-75
  • BMI 20-35kg/m\^2
  • Participants with type 2 diabetes:
  • HbA1c less than or equal to 8.5% on lifestyle therapy or monotherapy with metformin or sulphonylureas (SU); or less than or equal to 7.5% on two oral hypoglycemic agents (Metformin and SU)

You may not qualify if:

  • Pregnancy or breast feeding
  • Morbidities precluding participation
  • Participants with type 2 diabetes:
  • Therapy with insulin
  • SGLT2 inhibitors
  • GLP-1 based approaches
  • TZDs
  • Unstable diabetic retinopathy
  • Microalbuminuria
  • Macrovascular disease
  • Medications affecting GI motility (eg., erythromycin, pramlintide)
  • Upper GI disorder/surgery
  • Participants without diabetes:
  • Medications (except stable thyroid hormone or hormone replacement therapy) that could influence glucose tolerance
  • History of diabetes mellitus in first degree family members or prior history of diabetes mellitus or gestational diabetes, or pre-diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Virginia

Charlottesville, Virginia, 22908, United States

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Limitations and Caveats

• Though unlikely, it is possible that additional steps to load hepatic glycogen maybe necessary (e.g., late night snack: high carb in GL and isocaloric low carb in NGL) to maximize differences in liver glycogen contents between visits.

Results Point of Contact

Title
Dr. Rita Basu
Organization
University of Alabama at Birmingham

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
A total of 34 subjects participated.
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 1, 2020

First Posted

June 4, 2020

Study Start

August 21, 2020

Primary Completion

August 15, 2022

Study Completion

February 15, 2023

Last Updated

March 1, 2024

Results First Posted

December 18, 2023

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations